Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Armata PharmaceuticalsFRA:TG1N 33 EV-to-FCF is -22.55 as of Jul. 26, 2026. GuruFocus rates FRA:TG1N with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 343 Biotechnology companies, Armata Pharmaceuticals ranks worse than 291544.9% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Armata Pharmaceuticals's Enterprise Value is €474.66 Mil.
Armata Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-21.05 Mil. Therefore, Armata Pharmaceuticals's EV-to-FCF for today is -22.55.
The historical rank and industry rank for Armata Pharmaceuticals's EV-to-FCF or its related term are showing as below:
FRA:TG1N'
s EV-to-FCF Range Over the Past 10 Years
Min: -22.07 Med: -1.04 Max: 0.39
Current: -22.07
During the past 13 years, the highest EV-to-FCF of Armata Pharmaceuticals was 0.39. The lowest was -22.07. And the median was -1.04.
FRA:TG1N's EV-to-FCF is ranked worse than 100% of 343
companies
in the Biotechnology industry
Industry Median: 14.7
vs FRA:TG1N: -22.07
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Armata Pharmaceuticals (FRA:TG1N) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Armata Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Armata Pharmaceuticals's share price for today is €4.54.
Armata Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.682.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:TG1N vs NAGE, ALXO, LYEL: EV-to-FCF Comparison
For the Biotechnology subindustry, Armata Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Armata Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Armata Pharmaceuticals's EV-to-FCF falls into.
Armata Pharmaceuticals's current Enterprise Value is €474.66 Mil.
Armata Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-21.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Armata Pharmaceuticals (FRA:TG1N) has a EV-to-FCF of -22.55 as of Jul. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Armata Pharmaceuticals and its competitors. According to the industry distribution chart, Armata Pharmaceuticals ranks #999999 out of 343 companies in the Biotechnology industry.
Is Armata Pharmaceuticals' EV-to-FCF too high?
Armata Pharmaceuticals' current EV-to-FCF is -22.55. Based on the distribution chart, Armata Pharmaceuticals ranks #999999 out of 343 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Armata Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Armata Pharmaceuticals' EV-to-FCF compare to NAGE and ALXO?
According to the Biotechnology industry distribution chart, Armata Pharmaceuticals ranks #999999 out of 343 companies for EV-to-FCF. This places Armata Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 14.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.70, based on 343 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Armata Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Armata Pharmaceuticals's current EV-to-FCF is -22.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Armata Pharmaceuticals stock overvalued right now?
Armata Pharmaceuticals (FRA:TG1N) has a current EV-to-FCF of -22.55. The current EV-to-FCF is -22.55. Armata Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Armata Pharmaceuticals (FRA:TG1N), the current EV-to-FCF is -22.55 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
33GF Score
Get the complete analysis for FRA:TG1N
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TG1N has been successfully added to your 
